FDA Clearance Tracker · P940016-S014
HEPARIN-INDUCED EXTRACORPOREAL LIPOPROTEIN PRECIPITATION (H.E.L.P.) FUTURA APHERESIS SYSTEM
Last checked: Nov 20, 2026Latest source record: Jan 13, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Jan 13, 2012
Approved
Time to decision
178 days
Received Jul 19, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P940016-S014
- Device name
- HEPARIN-INDUCED EXTRACORPOREAL LIPOPROTEIN PRECIPITATION (H.E.L.P.) FUTURA APHERESIS SYSTEM
- Applicant
- B. Braun Avitum AG
- Applicant location
- Melsungen
- Received
- Jul 19, 2011
- Decided
- Jan 13, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P940016
Device type
- Device type
- Lipoprotein, low density, removal (MMY)
- Device class
- Class III
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A CHANGE IN THE POTTING RESIN USED TO ANCHOR THE MEMBRANES OF THE HEPARIN ADSORBER AND THE PLASMAFILTER HAEMOSELECT COMPONENTS OF THE SYSTEM.
Source documents
Other decisions for B. Braun Avitum AG
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Diacap Pro Dialyzer510(k)
K170574 · Decided Aug 11, 2017 · 165 days after receipt
Device type: Dialyzer, High Permeability With Or Without Sealed Dialysate System (KDI) · GI, Urology & Nephrology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.